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Over the last 20 years, the short- and long-term prognosis
of myocardial infarction (MI) has markedly improved. The
mortality rate, which was approximately 19% in 1986 (1),
now approaches 5% to 6%, at least in contemporary clinical
trials and registries (2–4). There are several potential
reasons for this decrease, one of which is the introduction of
effective techniques of myocardial reperfusion. It has been
clearly demonstrated that an important determinant of
prognosis in MI is the rapidity, extent, and durability of
reperfusion. Primary percutaneous coronary intervention
(PCI), which results in a higher reperfusion rate, has been
shown to be superior to fibrinolytic treatment, although the
latter is more widely available and can be administered more
quickly (5). New strategies, including pre-hospital throm-
bolysis with transfer to an interventional center for possible
rescue angioplasty, have been proposed and may be appro-
priate in situations where primary angioplasty is not feasible
for all patients (6,7). Despite these major advances, there
remains a black zone where progress has been less striking.
This is the case with cardiogenic shock, which remains the
severest clinical complication of MI.
See pages 1373 and 1380
The incidence of cardiogenic shock remains approxi-
mately 7% to 8% in a recent series of the literature (8,9), and
apparently, this incidence has not declined with modern
treatment. Cardiogenic shock can be present upon hospital
presentation or may develop at a later stage. It is very likely
that the heterogeneity in the timing of onset of cardiogenic
shock reflects the varying and complex underlying patho-
physiologic mechanisms. In this field, we have only partial
and limited information from small groups of patients who
underwent coronary angiography. In this issue of the Jour-
nal, Sanborn et al. (10) describes extensively the angio-
graphic characteristics of 243 patients enrolled in the
Should We Emergently Revascularize Occluded Coronaries
for Cardiogenic Shock (SHOCK) trial (11). This was a
multicenter, randomized trial conducted at 36 international
centers that compared two treatment strategies: one in-
cluded emergency revascularization, and the other included
initial medical stabilization. This trial showed a significantly
better survival at one year in patients who underwent
emergency revascularization (47%) compared with patients
who were initially medically stabilized (34%) (p  0.025).
As previously reported, 64% of the patients had severe
triple-vessel disease, and 21% had significant left main
stenosis. The most frequent culprit vessel was the left
anterior descending artery (49%), whereas the right coro-
nary artery was the infarct-related artery in 29% of cases.
Two-thirds of the infarct-related arteries had TIMI 0 to 2
flow at the culprit lesion, and this was more frequent in the
group with initial medical stabilization than in patients with
emergency revascularization. Disease severity was not cor-
related with one-year survival in this latter group, whereas a
significant correlation (p  0.02) was noted in the initially
medically treated group.
Although left ventricular (LV) ejection fraction was
strongly correlated with one-year survival, it appears that
LV function was moderately but not severely depressed,
suggesting that besides the extent of myocardial necrosis,
other factors, mainly peripheral, can play an important role.
The severity of mitral regurgitation (MR), which is corre-
lated with the mortality rate, is also important.
This report suggests for the first time the importance of
early reperfusion before revascularization, and these impor-
tant data raise two issues. First, would earlier reperfusion
with pre-hospital fibrinolysis reduce the incidence of car-
diogenic shock? Recent data from the Comparison of
Angioplasty and Prehospital Thrombolysis in Acute Myo-
cardial Infarction (CAPTIM) trial (7) showing a lower rate
of cardiogenic shock in the pre-hospital fibrinolytic group
support this hypothesis.
Second, this angiographic study demonstrates clearly the
impact of severe triple-vessel disease and left main narrow-
ing. This suggests that complete myocardial revasculariza-
tion could be of importance, as suggested in other limited
numbers of cases. Although coronary artery bypass grafting
is a high-risk procedure in these patients, it would be a good
way to tackle the key elements involved in cardiogenic
shock, that is, extension of coronary artery disease, left main
narrowing, and MR. With the exception of MR, modern
PCI with modern (drug-eluting) stents, as well as adjunctive
pharmacologic therapy (GP IIb/IIIa and clopidogrel), could
also play a more important role in the future. These issues
are addressed in a second report in this issue of the Journal
by Webb et al. (12), who examined the clinical, angio-
graphic, and procedural characteristics determining survival
among 82 patients who underwent PCI.
Percutaneous coronary intervention was performed at a
median time of 11 h in patients with a median time of 5.1 h
from onset of MI to shock. Although 81% of patients had
multivessel disease, most of them (87%) underwent a
single-vessel procedure. However, this trial was conducted
between 1993 and 1998, and thus, the rate of stenting and
GP IIb/IIIa usage does not reflect current practice in
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interventional cardiology. On average, one-third of the
patients had stent implantation at the site of the culprit
lesion, mainly as a backup for a failed balloon procedure.
The rate of coronary stenting culminated at 74% in the last
two years of the study. Similarly, the rate of GP IIb/IIIa use,
which was low (7%) in the first two-thirds of the study,
markedly increased over the last two years (81%).
It is important to note that the procedural success was
relatively low (76%) and significantly lower than the rate
currently achieved with modern angioplasty in acute MI.
This is of paramount importance because the survival rate
was 65% at 30 days and 61% at 1 year in those patients with
successful procedures. The corresponding survival rates in
patients in whom the procedure was unsuccessful were 20%
at 30 days and 15% at 1 year. Over time, and despite
significant advances (stents and GP IIb/IIIa), the one-year
survival rate remained unchanged. Thus, one can reasonably
ask the following question: Is there any hope for the future
in patients with cardiogenic shock?
The following three issues deserve consideration:
1. Faced with severe multiple-vessel disease in patients with
cardiogenic shock, interventional cardiologists should
strongly consider the option of complete or almost-
complete myocardial revascularization. New tools have
made it possible to treat more and more lesions effec-
tively, but this may require lengthy procedures, and it
increases the contrast load in these fragile patients. It is
important to note that in the study of Webb et al. (12),
the outcome of single-stage multivessel procedure was
rather disappointing because the one-year survival rate
was only 20% compared with 55% after single-vessel
angioplasty. Among the few patients in this trial who
underwent emergency coronary artery bypass grafting,
survival was 38%.
2. Mitral regurgitation seems to be an important predictor:
The survival rate was 64% in patients undergoing PCI
who did not have MR compared with only 18% for those
who had severe MR.
3. Hence, when confronted with severe lesions affecting the
three major vessels and associated MR, one might ask
whether it would not be a more reasonable option to
consider emergency coronary bypass surgery as an alter-
native to the relatively disappointing impact of PCI in
this subgroup.
Further trials are needed to assess the impact of modern,
innovative technologies and pharmacologic treatment. Sev-
eral techniques are under evaluation that might help reduce
the final infarct size. Systemic hypothermia has shown
initial promise in patients with relatively uncomplicated
acute MI, and several trials are underway to evaluate the real
clinical benefit (13). Other percutaneous options, such as
LV assist devices to allow time for recovery in partially
infarcted myocardium, also are under investigation (14).
However, for the moment, the prognosis of patients with
acute MI and cardiogenic shock remains extremely guarded.
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